Affinity Asset Advisors LLC Boosts Holdings in COMPASS Pathways plc (NASDAQ:CMPS)

Affinity Asset Advisors LLC grew its position in shares of COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 183.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 850,512 shares of the company's stock after buying an additional 550,000 shares during the quarter. Affinity Asset Advisors LLC owned 1.24% of COMPASS Pathways worth $3,215,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Conservest Capital Advisors Inc. raised its holdings in COMPASS Pathways by 28.9% during the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock valued at $51,000 after acquiring an additional 3,000 shares during the period. Kennedy Capital Management LLC increased its stake in shares of COMPASS Pathways by 22.8% in the fourth quarter. Kennedy Capital Management LLC now owns 33,976 shares of the company's stock worth $128,000 after buying an additional 6,297 shares during the period. Barclays PLC raised its holdings in COMPASS Pathways by 2.1% during the 4th quarter. Barclays PLC now owns 419,194 shares of the company's stock valued at $1,585,000 after buying an additional 8,718 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in COMPASS Pathways during the 4th quarter valued at $41,000. Finally, Wealthfront Advisers LLC bought a new stake in COMPASS Pathways in the 4th quarter worth $43,000. Hedge funds and other institutional investors own 46.19% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CMPS. HC Wainwright reaffirmed a "buy" rating and issued a $45.00 target price on shares of COMPASS Pathways in a research report on Tuesday, March 4th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of COMPASS Pathways in a report on Friday, March 28th. Royal Bank of Canada restated an "outperform" rating and set a $18.00 target price on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Stifel Nicolaus assumed coverage on COMPASS Pathways in a report on Thursday, February 27th. They set a "buy" rating and a $11.00 price target on the stock. Finally, Canaccord Genuity Group lowered their price objective on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $20.20.

COMPASS Pathways Trading Up 4.7 %

Shares of COMPASS Pathways stock traded up $0.14 on Friday, reaching $3.13. The company had a trading volume of 519,668 shares, compared to its average volume of 770,328. The firm's 50-day moving average price is $3.43 and its two-hundred day moving average price is $4.26. COMPASS Pathways plc has a 1 year low of $2.49 and a 1 year high of $9.63. The firm has a market cap of $290.07 million, a price-to-earnings ratio of -1.42 and a beta of 2.34. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). As a group, research analysts predict that COMPASS Pathways plc will post -2.33 earnings per share for the current fiscal year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.